{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:25:46Z","timestamp":1783124746715,"version":"3.54.6"},"reference-count":25,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T00:00:00Z","timestamp":1725753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","award":["2122-HQ-000070"],"award-info":[{"award-number":["2122-HQ-000070"]}],"id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Department of Medicine, University of Toronto","award":["2122-HQ-000070"],"award-info":[{"award-number":["2122-HQ-000070"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>We were tasked by Canada\u2019s COVID-19 Immunity Task Force to describe severe adverse events (SAEs) associated with emergency department (ED) visits and\/or hospitalizations in individuals with immune-mediated inflammatory diseases (IMIDs). At eight Canadian centres, data were collected from adults with rheumatoid arthritis (RA), axial spondyloarthritis (AxS), systemic lupus (SLE), psoriatic arthritis (PsA), and inflammatory bowel disease (IBD). We administered questionnaires, analyzing SAEs experienced within 31 days following SARS-CoV-2 vaccination. About two-thirds (63%) of 1556 participants were female; the mean age was 52.5 years. The BNT162b2 (Pfizer) vaccine was the most common, with mRNA-1273 (Moderna) being second. A total of 49% of participants had IBD, 27.4% had RA, 14.3% had PsA, 5.3% had SpA, and 4% had SLE. Twelve (0.77% of 1556 participants) SAEs leading to an ED visit or hospitalization were self-reported, occurring in 11 participants. SAEs included six (0.39% of 1556 participants) ED visits (including one due to Bell\u2019s Palsy 31 days after first vaccination) and six (0.39% of 1556 participants) hospitalizations (including one due to Guillain-Barr\u00e9 syndrome 15 days after the first vaccination). Two SAEs included pericarditis, one involved SLE (considered a serious disease flare), and one involved RA. Thus, in the 31 days after SARS-CoV-2 vaccination in our IMID sample, very few serious adverse events occurred. As SARS-CoV2 continues to be a common cause of death, our findings may help optimize vaccination acceptance.<\/jats:p>","DOI":"10.3390\/vaccines12091027","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T03:04:18Z","timestamp":1725851058000},"page":"1027","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["How Safe Are COVID-19 Vaccines in Individuals with Immune-Mediated Inflammatory Diseases? The SUCCEED Study"],"prefix":"10.3390","volume":"12","author":[{"given":"Olga","family":"Tsyruk","sequence":"first","affiliation":[{"name":"Department of Medicine, McGill University, Montreal, QC H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2719-0556","authenticated-orcid":false,"given":"Gilaad G.","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB T2N 4Z6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Fortin","sequence":"additional","affiliation":[{"name":"Centre de Recherche ARThrite-UL, Division of Rheumatology, Department of Medicine, CHU de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec City, QC G1V 4G2, Canada"},{"name":"Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec City, QC G1V 4G2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A","family":"Hitchon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3A 1R9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[{"name":"Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON M5T 2S8, Canada"},{"name":"Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON M5S 3H2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie J.","family":"Larch\u00e9","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, McMaster University, Hamilton, ON L8N 3Z5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Avina-Zubieta","sequence":"additional","affiliation":[{"name":"Arthritis Research Canada and Division of Rheumatology, University of British Columbia, Vancouver, BC V5Y 3P2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2481-5821","authenticated-orcid":false,"given":"Gilles","family":"Boire","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Universit\u00e9 de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Colmegna","sequence":"additional","affiliation":[{"name":"Department of Medicine, McGill University, Montreal, QC H4A 3J1, Canada"},{"name":"The Research Institute of the McGill University Health Centre, McGill University, Montreal, QC H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Lacaille","sequence":"additional","affiliation":[{"name":"Arthritis Research Canada and Division of Rheumatology, University of British Columbia, Vancouver, BC V5Y 3P2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Lalonde","sequence":"additional","affiliation":[{"name":"Canadian Arthritis Patient Alliance, Toronto, ON L6A 4Z6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Proulx","sequence":"additional","affiliation":[{"name":"Canadian Arthritis Patient Alliance, Toronto, ON L6A 4Z6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn P.","family":"Richards","sequence":"additional","affiliation":[{"name":"Canadian Arthritis Patient Alliance, Toronto, ON L6A 4Z6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Boivin","sequence":"additional","affiliation":[{"name":"Canadian Arthritis Patient Alliance, Toronto, ON L6A 4Z6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"DeBow","sequence":"additional","affiliation":[{"name":"Canadian Arthritis Patient Alliance, Toronto, ON L6A 4Z6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Kovalova-Wood","sequence":"additional","affiliation":[{"name":"Canadian Arthritis Patient Alliance, Toronto, ON L6A 4Z6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Paleczny","sequence":"additional","affiliation":[{"name":"Canadian Arthritis Patient Alliance, Toronto, ON L6A 4Z6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9719-318X","authenticated-orcid":false,"given":"Linda","family":"Wilhelm","sequence":"additional","affiliation":[{"name":"Canadian Arthritis Patient Alliance, Toronto, ON L6A 4Z6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luck","family":"Lukusa","sequence":"additional","affiliation":[{"name":"The Research Institute of the McGill University Health Centre, McGill University, Montreal, QC H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pereira","sequence":"additional","affiliation":[{"name":"Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON M5T 2S8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5501-0017","authenticated-orcid":false,"given":"Jennifer LF.","family":"Lee","sequence":"additional","affiliation":[{"name":"The Research Institute of the McGill University Health Centre, McGill University, Montreal, QC H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9515-2802","authenticated-orcid":false,"given":"Sasha","family":"Bernatsky","sequence":"additional","affiliation":[{"name":"Department of Medicine, McGill University, Montreal, QC H4A 3J1, Canada"},{"name":"The Research Institute of the McGill University Health Centre, McGill University, Montreal, QC H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the SUCCEED Investigative Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/acr.23743","article-title":"Trends in the Prevalence and Incidence of Psoriasis and Psoriatic Arthritis in Ontario, Canada: A Population-Based Study","volume":"71","author":"Eder","year":"2019","journal-title":"Arthritis. Care. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/art.38306","article-title":"The epidemiology of rheumatoid arthritis in Ontario, Canada","volume":"66","author":"Widdifield","year":"2014","journal-title":"Arthritis. Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e490","DOI":"10.1016\/S2665-9913(22)00098-4","article-title":"Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: A nationwide cohort study in the OpenSAFELY platform","volume":"4","author":"MacKenna","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.14309\/ajg.0000000000002337","article-title":"Adverse Events and Serological Responses After SARS-CoV-2 Vaccination in Individuals with Inflammatory Bowel Disease","volume":"118","author":"Markovinovic","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"ref_9","unstructured":"Vaccine Vigilance Working Group & PHAC (2024, September 03). Reporting Adverse Events Following Immunization (AEFI) in Canada: User Guide to Completion and Submission of the AEFI Reports. Government of Canada. Available online: https:\/\/www.canada.ca\/en\/public-health\/services\/immunization\/reporting-adverse-events-following-immunization\/user-guide-completion-submission-aefi-reports.html."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e807","DOI":"10.1002\/iid3.807","article-title":"Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia","volume":"11","author":"Yasmin","year":"2023","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1016\/j.vaccine.2022.08.036","article-title":"Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults","volume":"40","author":"Fraiman","year":"2022","journal-title":"Vaccine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00296-021-04972-7","article-title":"Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"41","author":"Bartels","year":"2021","journal-title":"Rheumatol. Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1093\/rheumatology\/keac624","article-title":"COVID-19 vaccination in autoimmune diseases (COVAD) study: Vaccine safety and tolerance in rheumatoid arthritis","volume":"62","author":"Naveen","year":"2023","journal-title":"Rheumatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.14309\/ajg.0000000000001342","article-title":"Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease","volume":"116","author":"Botwin","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1080\/17512433.2022.2120466","article-title":"BNT162b2 mRNA COVID-19 vaccine is safe in a setting of patients on biologic therapy with inflammatory bowel diseases: A monocentric real-life study","volume":"15","author":"Pellegrino","year":"2022","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref_16","first-page":"58","article-title":"Safety of CoronaVac and ChAdOx1 vaccines against SARS-CoV-2 in patients with rheumatoid arthritis: Data from the Brazilian multicentric study SAFER","volume":"64","author":"Cruz","year":"2024","journal-title":"J. Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1007\/s10067-022-06253-5","article-title":"An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: The SAR-CoVAC Registry-protocol and preliminary data","volume":"41","author":"Isnardi","year":"2022","journal-title":"Clin. Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/ana.26339","article-title":"contributors from the Global COVID-19 Neuro Research Coalition. Neurological events reported after COVID-19 vaccines: An analysis of VAERS","volume":"91","author":"Frontera","year":"2022","journal-title":"Ann. Neurol."},{"key":"ref_19","first-page":"e37578","article-title":"Guillain-Barr\u00e9 syndrome induced by vaccination against COVID-19: A systematic review and meta-analysis","volume":"15","author":"Ogunjimi","year":"2023","journal-title":"Cureus"},{"key":"ref_20","unstructured":"Government of Canada (2024, September 03). Reported Side Effects Following COVID-19 Vaccination in Canada. Available online: https:\/\/health-infobase.canada.ca\/covid-19\/vaccine-safety\/."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/S2589-7500(22)00125-X","article-title":"Menstrual irregularities and vaginal bleeding after COVID-19 vaccination reported to v-safe active surveillance, USA in December, 2020-January, 2022: An observational cohort study","volume":"4","author":"Wong","year":"2022","journal-title":"Lancet. Digit. Health"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e13947","DOI":"10.1111\/eci.13947","article-title":"COVID-19 vaccine induced myocarditis in young males: A systematic review","volume":"53","author":"Knudsen","year":"2023","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2252239","DOI":"10.1080\/21645515.2023.2252239","article-title":"Thromboembolism after Astra Zeneca COVID-19 vaccine: Not always PF4- antibody mediated","volume":"19","author":"Markovic","year":"2023","journal-title":"Hum. Vaccines. Immunother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4049\/jimmunol.2300190","article-title":"Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARS-CoV-2 in Adult Patients with Immune-Mediated Inflammatory Diseases","volume":"211","author":"Cheung","year":"2023","journal-title":"J. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"22846","DOI":"10.1038\/s41598-023-50263-5","article-title":"Immunomodulatory drugs have divergent effects on humoral and cellular immune responses to SARS-CoV-2 vaccination in people living with rheumatoid arthritis","volume":"13","author":"Benoit","year":"2023","journal-title":"Sci. Rep."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/9\/1027\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:51:35Z","timestamp":1760111495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/9\/1027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,8]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["vaccines12091027"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12091027","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,8]]}}}